IBDEI1GI ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23558,1,3,0)
 ;;=3^Personal Hx of Nicotine Dependence
 ;;^UTILITY(U,$J,358.3,23558,1,4,0)
 ;;=4^Z87.891
 ;;^UTILITY(U,$J,358.3,23558,2)
 ;;=^5063518
 ;;^UTILITY(U,$J,358.3,23559,0)
 ;;=E13.9^^79^1017^9
 ;;^UTILITY(U,$J,358.3,23559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23559,1,3,0)
 ;;=3^Diabetes Mellitus w/o Complications,Other Spec
 ;;^UTILITY(U,$J,358.3,23559,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,23559,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,23560,0)
 ;;=R94.8^^79^1017^4
 ;;^UTILITY(U,$J,358.3,23560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23560,1,3,0)
 ;;=3^Abnormal Results of Function Studies of Organs/Systems
 ;;^UTILITY(U,$J,358.3,23560,1,4,0)
 ;;=4^R94.8
 ;;^UTILITY(U,$J,358.3,23560,2)
 ;;=^5019745
 ;;^UTILITY(U,$J,358.3,23561,0)
 ;;=Z63.4^^79^1017^7
 ;;^UTILITY(U,$J,358.3,23561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23561,1,3,0)
 ;;=3^Bereavement
 ;;^UTILITY(U,$J,358.3,23561,1,4,0)
 ;;=4^Z63.4
 ;;^UTILITY(U,$J,358.3,23561,2)
 ;;=^5063168
 ;;^UTILITY(U,$J,358.3,23562,0)
 ;;=Z45.2^^79^1017^5
 ;;^UTILITY(U,$J,358.3,23562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23562,1,3,0)
 ;;=3^Adjustment & Management of VAD
 ;;^UTILITY(U,$J,358.3,23562,1,4,0)
 ;;=4^Z45.2
 ;;^UTILITY(U,$J,358.3,23562,2)
 ;;=^5062999
 ;;^UTILITY(U,$J,358.3,23563,0)
 ;;=Z76.0^^79^1017^18
 ;;^UTILITY(U,$J,358.3,23563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23563,1,3,0)
 ;;=3^Issue of Repeat Prescription
 ;;^UTILITY(U,$J,358.3,23563,1,4,0)
 ;;=4^Z76.0
 ;;^UTILITY(U,$J,358.3,23563,2)
 ;;=^5063297
 ;;^UTILITY(U,$J,358.3,23564,0)
 ;;=Z01.818^^79^1017^26
 ;;^UTILITY(U,$J,358.3,23564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23564,1,3,0)
 ;;=3^Pre-Op Call
 ;;^UTILITY(U,$J,358.3,23564,1,4,0)
 ;;=4^Z01.818
 ;;^UTILITY(U,$J,358.3,23564,2)
 ;;=^5062628
 ;;^UTILITY(U,$J,358.3,23565,0)
 ;;=Z51.81^^79^1017^27
 ;;^UTILITY(U,$J,358.3,23565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23565,1,3,0)
 ;;=3^Therapeutic Drug Level Monitoring
 ;;^UTILITY(U,$J,358.3,23565,1,4,0)
 ;;=4^Z51.81
 ;;^UTILITY(U,$J,358.3,23565,2)
 ;;=^5063064
 ;;^UTILITY(U,$J,358.3,23566,0)
 ;;=I10.^^79^1017^17
 ;;^UTILITY(U,$J,358.3,23566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23566,1,3,0)
 ;;=3^Hypertension
 ;;^UTILITY(U,$J,358.3,23566,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,23566,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,23567,0)
 ;;=Z79.01^^79^1017^20
 ;;^UTILITY(U,$J,358.3,23567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23567,1,3,0)
 ;;=3^Long Term (Current) Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,23567,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,23567,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,23568,0)
 ;;=R73.09^^79^1017^3
 ;;^UTILITY(U,$J,358.3,23568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23568,1,3,0)
 ;;=3^Abnormal Glucose
 ;;^UTILITY(U,$J,358.3,23568,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,23568,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,23569,0)
 ;;=R68.89^^79^1017^13
 ;;^UTILITY(U,$J,358.3,23569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23569,1,3,0)
 ;;=3^General Symptoms & Signs
 ;;^UTILITY(U,$J,358.3,23569,1,4,0)
 ;;=4^R68.89
 ;;^UTILITY(U,$J,358.3,23569,2)
 ;;=^5019557
 ;;^UTILITY(U,$J,358.3,23570,0)
 ;;=R79.89^^79^1017^1
 ;;^UTILITY(U,$J,358.3,23570,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23570,1,3,0)
 ;;=3^Abnormal Findings of Blood Chemistry
 ;;^UTILITY(U,$J,358.3,23570,1,4,0)
 ;;=4^R79.89
